You make good points as well. We can all agree there is a problem here thus far; fundamentally we don't know if it's the "product", the sales and marketing, mispriced, industry slow to change, management or what.
As Z says the EAP was supposed to help to "develop" the product at least to be worth paying for, and let the scientists check it out and report back, work with Cola on it, so on, but if nobody steps up to throw a bone at this after the EAP program ends, then more likely than not the software is the problem, and you'd be right not to blame sales/marketing.
All my opinion.
GL
News 
Market Data 
Discover 
